Anzeige
Mehr »
Samstag, 30.08.2025 - Börsentäglich über 12.000 News
Megatrend Uran: Die Nachfrage nach Uran explodiert - greift jetzt Buffetts Erfolgsrezept?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40H8H | ISIN: BE0974487192 | Ticker-Symbol: TG40
Frankfurt
29.08.25 | 21:40
0,004 Euro
0,00 % 0,000
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
OXURION NV Chart 1 Jahr
5-Tage-Chart
OXURION NV 5-Tage-Chart

Aktuelle News zur OXURION Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07.08.OXURION: Oxurion Ends RD Program in Geographic Atrophy and Refocuses on New CRO Activities359Leuven, BELGIUM - August 7, 2025 - 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced the definitive termination of its preclinical...
► Artikel lesen
OXURION Aktie jetzt für 0€ handeln
07.08.OXURION: Oxurion Receives Transparency Notifications from UBS Group AG644Leuven, BELGIUM - August 7, 2025 - 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency...
► Artikel lesen
06.08.OXURION: Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC260Leuven, BELGIUM - August 6, 2025 - 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency...
► Artikel lesen
04.08.OXURION: Oxurion announces it obtained an improved indicative EUR 30 million financing offer to initiate its plan to diversify by allocating part of its treasury into digital assets349Leuven, Belgium, August 4, 2025 - 06:00 PM CEST - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, announces that it has received an improved indicative financing...
► Artikel lesen
04.08.OXURION: Oxurion completes the acquisition of Axiodis CRO and accelerates the structuring of its European clinical data platform267Oxurion announces the full completion of the acquisition of a 72% equity stake in Axiodis CRO This transaction marks the first step in building an integrated platform focused on clinical data The...
► Artikel lesen
30.07.OXURION: Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas376Atlas Special Opportunities, LLC has converted 12 convertible bonds in Oxurion resulting in a EUR 300,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital...
► Artikel lesen
30.07.OXURION: Oxurion Receives Amended Transparency Notification from Atlas Special Opportunities II LLC264Leuven, BELGIUM - July 30, 2025 - 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency...
► Artikel lesen
23.07.OXURION: Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas370Atlas Special Opportunities, LLC has converted 5 convertible bonds in Oxurion resulting in a EUR 125,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital...
► Artikel lesen
22.07.OXURION: Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC289Leuven, BELGIUM - July 22, 2025 - 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency...
► Artikel lesen
22.07.OXURION: Oxurion plans to launch a treasury diversification strategy into digital assets under a EUR 10M indicative agreement with its main investor319This initiative is part of a long-term strategy for financial consolidation and growth support. Oxurion enters negotiations with Atlas Special Opportunities for a new €10 million convertible...
► Artikel lesen
17.07.OXURION: Oxurion Secures Financing for the Acquisition of Axiodis CRO and Targets Closing on August 1, 2025356Leuven, BELGIUM - July 17, 2025 at 8:30 AM CET, Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, announces it has secured the financing for the acquisition of...
► Artikel lesen
15.07.OXURION: Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC360Leuven, BELGIUM - July 15, 2025 - 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency...
► Artikel lesen
14.07.OXURION: Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC315Leuven, BELGIUM - July 14, 2025 - 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency...
► Artikel lesen
10.07.OXURION: Oxurion Announces the Fulfilment of the Second Condition Precedent in the Acquisition of Axiodis537Leuven, BELGIUM - July 10, 2025 at 5:45 PM CET, Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, announces the fulfilment of the second condition precedent in...
► Artikel lesen
04.07.OXURION: Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas462Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital...
► Artikel lesen
03.07.OXURION: Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC397Leuven, BELGIUM - July 3, 2025 - 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency...
► Artikel lesen
25.06.OXURION: Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC359Leuven, BELGIUM - June 25, 2025 - 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency...
► Artikel lesen
19.06.OXURION: Oxurion signs a letter of intent for the planned acquisition of a preclinical microbiology CRO to diversify and strengthen its presence in the Toulouse region448Leuven, BELGIUM - June 19, 2025 at 8:30 AM CET, Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, announces the signing of a letter of intent (LOI) to acquire 70%...
► Artikel lesen
18.06.OXURION: Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC395Leuven, BELGIUM - June 18, 2025 - 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency...
► Artikel lesen
12.06.OXURION: Oxurion Receives Amended Transparency Notification from Atlas Special Opportunities II LLC398Leuven, BELGIUM - June 12, 2025 - 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency...
► Artikel lesen
Weiter >>
72 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1